Teriparatide Reduces Osteoporosis Pain and Bone Loss in a Mouse Model
Teriparatide (PTH peptide) prevents bone loss and reduces pain in ovariectomized mice by suppressing CGRP and TRPV1 expression in pain-sensing neurons.
Quick Facts
What This Study Found
Teriparatide prevents ovariectomy-induced bone loss, reduces mechanical hyperalgesia, and suppresses CGRP and TRPV1 upregulation in dorsal root ganglion neurons innervating affected limbs.
Key Numbers
4-week treatment; prevented bone loss on micro-CT; reduced mechanical hyperalgesia; lowered CGRP and TRPV1 expression in DRG neurons
How They Did This
Three groups of ovariectomized/sham mice, 4-week subcutaneous teriparatide treatment, von Frey filament mechanical sensitivity testing, microCT bone analysis, immunohistochemistry of DRG neurons.
Why This Research Matters
Many osteoporosis patients suffer from chronic pain that isn't fully addressed by bone-strengthening drugs. Teriparatide uniquely treats both bone loss and associated pain by modulating neuropeptide signaling.
The Bigger Picture
This finding positions teriparatide as a dual-action therapy for postmenopausal osteoporosis — building bone while simultaneously addressing pain through neuropeptide pathway modulation.
What This Study Doesn't Tell Us
Mouse study with unclear translation to humans. Small group sizes not specified. Only 4 weeks of treatment with no long-term follow-up.
Questions This Raises
- ?Does teriparatide reduce osteoporotic pain in human patients?
- ?Is the pain-reducing effect sustained after treatment stops?
- ?Could teriparatide's neuropeptide modulation help with other chronic pain conditions?
Trust & Context
- Key Stat:
- Dual action Teriparatide both prevented bone loss and reduced pain by suppressing neuropeptide expression in DRG neurons
- Evidence Grade:
- Animal study demonstrating both bone and pain outcomes. Preliminary evidence that needs human clinical confirmation.
- Study Age:
- Published in 2020. Teriparatide is already clinically used for osteoporosis, making the pain findings clinically translatable.
- Original Title:
- Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice.
- Published In:
- Journal of orthopaedic surgery (Hong Kong), 28(1), 2309499019893194 (2020)
- Authors:
- Kato, Sho, Wakabayashi, Hiroki, Nakagawa, Taro, Miyamura, Gaku, Naito, Yohei, Iino, Takahiro, Sudo, Akihiro
- Database ID:
- RPEP-04900
Evidence Hierarchy
Frequently Asked Questions
What is teriparatide?
Teriparatide is a synthetic version of parathyroid hormone (PTH), a peptide naturally produced by the body. It's approved for treating severe osteoporosis and works by stimulating new bone formation rather than just slowing bone breakdown.
How does teriparatide reduce pain?
The study found teriparatide suppresses CGRP and TRPV1, two molecules involved in pain signaling, in the nerve cells that sense pain from bones. By reducing these pain mediators, teriparatide addresses both the structural and sensory aspects of osteoporosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04900APA
Kato, Sho; Wakabayashi, Hiroki; Nakagawa, Taro; Miyamura, Gaku; Naito, Yohei; Iino, Takahiro; Sudo, Akihiro. (2020). Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice.. Journal of orthopaedic surgery (Hong Kong), 28(1), 2309499019893194. https://doi.org/10.1177/2309499019893194
MLA
Kato, Sho, et al. "Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice.." Journal of orthopaedic surgery (Hong Kong), 2020. https://doi.org/10.1177/2309499019893194
RethinkPeptides
RethinkPeptides Research Database. "Teriparatide improves pain-related behavior and prevents bon..." RPEP-04900. Retrieved from https://rethinkpeptides.com/research/kato-2020-teriparatide-improves-painrelated-behavior
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.